← Browse by Condition
Medical Condition

esophageal squamous cell carcinoma escc

Total Trials
7
Recruiting Now
7
Trial Phases
Phase 2, Phase 1, Phase 2, Phase 3

ClinicalMetric tracks all active clinical trials for esophageal squamous cell carcinoma escc sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — esophageal squamous cell carcinoma escc Clinical Trials

How many clinical trials are currently recruiting for esophageal squamous cell carcinoma escc?
ClinicalMetric currently tracks 7 actively recruiting clinical trials for esophageal squamous cell carcinoma escc, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 7. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for esophageal squamous cell carcinoma escc?
esophageal squamous cell carcinoma escc research spans Phase 1 (1 trial), Phase 2 (6 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a esophageal squamous cell carcinoma escc clinical trial?
Eligibility criteria for esophageal squamous cell carcinoma escc trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
6
Phase 3
1
Top Sponsors
University Hospital, Clermont-Ferrand 1 trial
Second Affiliated Hospital of Zunyi Medical University 1 trial
Sichuan University 1 trial
AP Biosciences Inc. 1 trial
Hebei Medical University Fourth Hospital 1 trial

Recruiting Clinical Trials

NCT07205731 Phase 2
Recruiting
Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma
Enrollment
95 pts
Location
France
Sponsor
University Hospital, Clermont-...
View Trial →
NCT07559045 Phase 2
Recruiting
Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
Enrollment
92 pts
Location
China
Sponsor
Second Affiliated Hospital of ...
View Trial →
NCT06603402 Phase 2
Recruiting
Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC
Enrollment
41 pts
Location
China
Sponsor
Sichuan University
View Trial →
NCT05473156 Phase 1, Phase 2
Recruiting
A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies
Enrollment
168 pts
Location
Taiwan
Sponsor
AP Biosciences Inc.
View Trial →
NCT07290010 Phase 2
Recruiting
The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma
Enrollment
25 pts
Location
China
Sponsor
Hebei Medical University Fourt...
View Trial →
NCT07638436 Phase 2
Recruiting
Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Enrollment
42 pts
Location
China
Sponsor
Sun Yat-sen University
View Trial →
NCT07463573 Phase 3
Recruiting
QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Enrollment
466 pts
Location
China
Sponsor
Qilu Pharmaceutical Co., Ltd.
View Trial →

Related Conditions

immunotherapy (1) locally advanced or metastatic solid tumors (1) non small cell lung cancer nsclc (1) head and neck squamous cell carcinoma hnscc (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology